Cell & Gene Therapy
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
BrainStorm cuts 30% staff, eyes ALS cell therapy approval
BrainStorm Cell Therapeutics has chosen an unconventional route in response to its recent setback in securing approval. While the decision ...
Moderna, BioNTech face hurdles in cancer vaccine production after COVID success
Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...
BioNTech’s CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
Nkarta’s breakthrough cell therapy for lupus gets FDA approval after showing promise in cancer treatment
In a groundbreaking development, Nkarta is pushing the boundaries of cell therapy beyond the realm of cancer. The FDA has ...
SpliceBio and Roche’s Spark Therapeutics team up for eye disease gene therapy
SpliceBio Initiates $216 Million Collaboration with Roche’s Gene Therapy Unit to Pave the Way for Innovative Inherited Retinal Disease Treatment ...
Sana slashes staff and drops in vivo CAR-T program to cut costs
Sana Biotechnology, amid challenging stock performance, is undergoing its second significant restructuring in less than a year. This move involves ...
QHP acquires Applied StemCell to strengthen its cell and gene therapy services for pharma clients
QHP Capital is expanding its portfolio of contract service providers by acquiring Applied StemCell (ASC), a specialized company in cell ...
Kyowa Kirin to buy Orchard Therapeutics for $387M, expanding gene therapy portfolio
Kyowa Kirin has responded to the need to strengthen its late-phase pipeline by finalizing a deal to acquire Orchard Therapeutics ...
uniQure cuts staff and R&D projects to extend gene therapy cash runway
uniQure, a biotech company focused on gene therapy, is implementing a significant workforce reduction as part of a strategic restructuring ...
AbbVie drops Caribou’s CRISPR-edited CAR-T therapies after failed trials
AbbVie has chosen to end its partnership with Caribou Biosciences, signaling a significant shift in its strategic focus. This decision ...
Novo Nordisk Foundation Cellerator to boost cell therapy development and production in Denmark
The Novo Nordisk Foundation is embarking on a mission to establish a pivotal “hub” within the cell therapy ecosystem by ...
Mesoblast hopes to win FDA approval for remestemcel-L after meeting with regulators
Mesoblast, a biotech company based in Melbourne, Australia, is making determined strides toward securing FDA approval for its off-the-shelf therapy, ...
Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback
Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...
Nobel Prize Winner in Chemistry Joins Acepodia to Develop Novel Cell Therapies for Cancer
Renowned Nobel laureate Carolyn Bertozzi, Ph.D., has joined Acepodia as its Chief Scientific Adviser, marking a significant development in the ...
Hemogenyx clears FDA hurdle for its novel CAR-T therapy for AML
Hemogenyx Pharmaceuticals has moved a step closer to advancing its CAR-T therapy, HEMO-CAR-T, into clinical trials following the FDA’s acceptance ...
2seventy Bio slashes 176 jobs and looks for new CEO after cell therapy setback
2seventy bio, the spinoff from bluebird bio, is undergoing significant changes under the leadership of CEO Nick Leschly. The company ...
BlueWhale Bio Emerges With $18m To Tackle Cell Therapy Manufacturing Challenges
BlueWhale Bio, a spinout from the University of Pennsylvania, has emerged with a bold mission to tackle bottlenecks in the ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
BioCardia’s cell therapy fails to improve heart failure outcomes in Phase 3 trial
BioCardia’s attempts to revive its paused phase 3 heart failure trial have hit a major setback, as results fail to ...
